12.21
price up icon2.35%   0.28
after-market Dopo l'orario di chiusura: 12.21
loading
Precedente Chiudi:
$11.93
Aprire:
$11.93
Volume 24 ore:
533.00K
Relative Volume:
0.93
Capitalizzazione di mercato:
$514.21M
Reddito:
$82.71M
Utile/perdita netta:
$-102.24M
Rapporto P/E:
-2.609
EPS:
-4.68
Flusso di cassa netto:
$-76.57M
1 W Prestazione:
-0.33%
1M Prestazione:
-3.86%
6M Prestazione:
-14.62%
1 anno Prestazione:
+5.53%
Intervallo 1D:
Value
$11.65
$12.30
Intervallo di 1 settimana:
Value
$11.65
$13.33
Portata 52W:
Value
$10.60
$20.70

Urogen Pharma Ltd Stock (URGN) Company Profile

Name
Nome
Urogen Pharma Ltd
Name
Telefono
972 9 770 7601
Name
Indirizzo
9 HA'TA'ASIYA ST, RA'ANANA
Name
Dipendente
203
Name
Cinguettio
@UroGenPharma
Name
Prossima data di guadagno
2024-11-06
Name
Ultimi documenti SEC
Name
URGN's Discussions on Twitter

Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2023-02-08 Downgrade Jefferies Buy → Hold
2022-04-27 Iniziato Berenberg Buy
2020-04-16 Reiterato H.C. Wainwright Buy
2020-04-13 Reiterato H.C. Wainwright Buy
2020-01-09 Iniziato National Securities Neutral
2019-05-30 Iniziato JP Morgan Neutral
2019-05-29 Iniziato Goldman Neutral
2019-01-29 Iniziato H.C. Wainwright Buy
2018-11-08 Ripresa Jefferies Buy
2018-04-04 Aggiornamento Raymond James Mkt Perform → Outperform
2018-01-02 Iniziato Ladenburg Thalmann Buy
2017-11-15 Reiterato Oppenheimer Outperform
2017-11-15 Downgrade Raymond James Outperform → Mkt Perform
Mostra tutto

Urogen Pharma Ltd Borsa (URGN) Ultime notizie

pulisher
08:48 AM

URGNUroGen Pharma Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan

08:48 AM
pulisher
08:00 AM

UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference - StockTitan

08:00 AM
pulisher
Nov 04, 2024

(URGN) Investment Analysis - Stock Traders Daily

Nov 04, 2024
pulisher
Nov 02, 2024

Rice Hall James & Associates LLC Grows Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat

Nov 02, 2024
pulisher
Oct 31, 2024

UroGen Pharma (URGN) to Release Quarterly Earnings on Wednesday - MarketBeat

Oct 31, 2024
pulisher
Oct 30, 2024

UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024 - BioSpace

Oct 30, 2024
pulisher
Oct 28, 2024

ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC - StockTitan

Oct 28, 2024
pulisher
Oct 25, 2024

(URGN) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Oct 25, 2024
pulisher
Oct 21, 2024

UroGen started at buy by EF Hutton, RTGel technology cited - MSN

Oct 21, 2024
pulisher
Oct 19, 2024

Investors in UroGen Pharma (NASDAQ:URGN) have unfortunately lost 42% over the last five years - Yahoo Finance

Oct 19, 2024
pulisher
Oct 17, 2024

FDA accepts UroGen's NDA for bladder cancer treatment - Investing.com India

Oct 17, 2024
pulisher
Oct 16, 2024

When Would Be The Best Time To Buy UroGen Pharma Ltd (NASDAQ: URGN) Stock? - Stocks Register

Oct 16, 2024
pulisher
Oct 16, 2024

URGN’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle

Oct 16, 2024
pulisher
Oct 16, 2024

UroGen Pharma maintains Outperform stock rating on new drug application - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

UroGen Pharma Ltd (URGN) looking to reclaim success with recent performance - SETE News

Oct 16, 2024
pulisher
Oct 16, 2024

UroGen Pharma maintains Outperform stock rating on new drug application By Investing.com - Investing.com UK

Oct 16, 2024
pulisher
Oct 16, 2024

UroGen Pharma (NASDAQ:URGN) Receives "Outperform" Rating from Oppenheimer - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

Wesbanco Bank Inc. Buys Shares of 74,400 UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

FDA accepts UroGen’s UGN-102 NDA for bladder cancer treatment - Pharmaceutical Technology

Oct 16, 2024
pulisher
Oct 15, 2024

UroGen Pharma Says FDA Accepts NDA for UGN-102 - Marketscreener.com

Oct 15, 2024
pulisher
Oct 15, 2024

UroGen Announces FDA Acceptance of its New Drug Application for UGN-102 - The Bakersfield Californian

Oct 15, 2024
pulisher
Oct 15, 2024

UroGen Pharma Ltd (URGN) is a good investment, but the stock may be undervalued - US Post News

Oct 15, 2024
pulisher
Oct 15, 2024

UroGen Pharma's (URGN) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

Oct 15, 2024
pulisher
Oct 15, 2024

UroGen Pharma (NASDAQ:URGN) Lifted to Strong-Buy at EF Hutton Acquisition Co. I - MarketBeat

Oct 15, 2024
pulisher
Oct 14, 2024

EF Hutton initiates UroGen Pharma shares with Buy rating By Investing.com - Investing.com South Africa

Oct 14, 2024
pulisher
Oct 14, 2024

EF Hutton Initiates Coverage of UroGen Pharma (URGN) with Buy Recommendation - MSN

Oct 14, 2024
pulisher
Oct 11, 2024

UroGen Pharma Ltd [URGN] Chief Medical Officer makes an insider sale of 859 shares worth 11,236. - Knox Daily

Oct 11, 2024
pulisher
Oct 10, 2024

Healthy Upside Potential: UroGen Pharma Ltd (URGN) - SETE News

Oct 10, 2024
pulisher
Oct 09, 2024

UroGen Pharma announces executive changes By Investing.com - Investing.com South Africa

Oct 09, 2024
pulisher
Oct 09, 2024

UroGen Pharma Ltd (URGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance

Oct 09, 2024
pulisher
Oct 09, 2024

UroGen Pharma Announces Departure of CFO and Appointment of New CFO - MarketBeat

Oct 09, 2024
pulisher
Oct 09, 2024

UroGen Appoints Chris Degnan as Chief Financial Officer - citybiz

Oct 09, 2024
pulisher
Oct 09, 2024

UroGen Pharma announces executive changes - Investing.com

Oct 09, 2024
pulisher
Oct 09, 2024

Urogen Pharma falls on CFO appointment - XM

Oct 09, 2024
pulisher
Oct 09, 2024

UroGen Pharma Announces CFO Transition and Compensation Details - TipRanks

Oct 09, 2024
pulisher
Oct 09, 2024

UroGen Pharma appoints Chris Degnan as CFO - Investing.com

Oct 09, 2024
pulisher
Oct 09, 2024

Marshall Wace LLP Buys Shares of 42,841 UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat

Oct 09, 2024
pulisher
Oct 08, 2024

News: UroGen Pharma Ltd’s Chief Medical Officer Schoenberg Mark reduceds 859 shares - Knox Daily

Oct 08, 2024
pulisher
Oct 08, 2024

What technical indicators reveal about URGN stock - US Post News

Oct 08, 2024
pulisher
Oct 08, 2024

Market Update: UroGen Pharma Ltd (URGN) Sees Negative Movement, Closing at 12.42 - The Dwinnex

Oct 08, 2024
pulisher
Oct 05, 2024

Millennium Management LLC Purchases 1,119,019 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat

Oct 05, 2024
pulisher
Oct 04, 2024

UroGen Pharma (STU:UR8) 9-Day RSI : 49.01 (As of Nov. 03, 2024) - GuruFocus.com

Oct 04, 2024
pulisher
Oct 04, 2024

UroGen begins subject dosing in Phase III bladder cancer drug trial - Clinical Trials Arena

Oct 04, 2024
pulisher
Oct 03, 2024

UroGen Pharma retains Buy rating from H.C. Wainwright By Investing.com - Investing.com Australia

Oct 03, 2024
pulisher
Oct 03, 2024

UroGen Pharma (NASDAQ:URGN) Given "Buy" Rating at HC Wainwright - MarketBeat

Oct 03, 2024
pulisher
Oct 02, 2024

URGN (UroGen Pharma Ltd) may reap gains as insiders became active recently - Knox Daily

Oct 02, 2024
pulisher
Oct 02, 2024

Stock Surge: UroGen Pharma Ltd (URGN) Closes at 12.48, Marking a -1.73 Increase/Decrease - The Dwinnex

Oct 02, 2024
pulisher
Oct 02, 2024

First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer - Business Wire

Oct 02, 2024
pulisher
Oct 01, 2024

Is the UroGen Pharma Ltd (NASDAQ:URGN) stock an investment opportunity? - US Post News

Oct 01, 2024
pulisher
Sep 26, 2024

UroGen Pharma Ltd. (NASDAQ:URGN) Shares Acquired by Point72 Asset Management L.P. - MarketBeat

Sep 26, 2024
pulisher
Sep 25, 2024

UroGen Pharma secures $25M loan, eyes FDA drug approval By Investing.com - Investing.com Australia

Sep 25, 2024

Urogen Pharma Ltd Azioni (URGN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Capitalizzazione:     |  Volume (24 ore):